Of note, a nanodrug delivery system co-loaded with icariin and Tan IIA liposomes was able to pass the BBB and improve AD-like pathological features, including inhibiting neuroinflammation and oxidative stress, reducing apoptosis, protecting neurons, and ultimately enhancing cognitive function by targeting low-density lipoprotein receptor-related protein-1 (LRP1) and Angiopep-2-modified long-circulating (Ang2) in APP/PS1 mice [95]. This evidence concerns the gene LRP1 and Alzheimer disease.